ADR 120S Co., Ltd. FY2026 Analysis: Guidance Points to Significant Revenue Rebound
ADR 120S Co., Ltd. (TSE:3750), a company specializing in regenerative medicine, medical devices, and medical tourism, reported its full-year results for the fiscal year ending March 2026. While the company posted a significant decline in revenue, management provided a detailed explanation suggesting the downturn was due to temporary sales timing adjustments rather than underlying demand issues, underpinning a strong positive outlook for the subsequent fiscal year.
| Metric | Current Period (JPY M) | Previous Period (JPY M) | YoY Change |
|---|---|---|---|
| Revenue | 50 | 122 | -58.3% |
| Operating Profit | -906,000,000 | -806,000,000 | N/A |
| Ordinary Income | -922,000,000 | -864,000,000 | N/A |
| Net Profit | -396,000,000 | -2,140,000,000 | N/A |
| Operating Margin | -1812.0% | N/A | N/A |
| Equity Ratio | 6.0% | 11.8% | N/A |
ADR 120S Co., Ltd. focuses on core areas including regenerative medicine, medical devices, and cellular therapy, with a noted emphasis on sports medicine applications.
The financial results reflect a substantial contraction in top-line revenue, falling 58.3% year-over-year to JPY 50M. Consequently, the Operating Margin registered at -1812.0%. While the absolute value of the Net Profit loss narrowed to -JPY 396,000,000 from the previous period’s -JPY 2,140,000,000, the decline in revenue has severely impacted profitability metrics. Furthermore, the Equity Ratio has declined to 6.0% from 11.8%, signaling a notable shift in the company’s capital structure.
Management has clarified that the sharp revenue decrease is not attributable to a decline in market demand or operational stagnation. Instead, the primary cause was the adjustment of the sales schedule for the medical device “Cellation Centrifuge,” which was postponed from post-development completion until August 2026. This explanation frames the revenue dip as a temporary, strategic operational adjustment necessary for quality assurance and scaling up mass production capabilities.
Next Year Guidance
| Metric | Forecast (JPY M) | Vs. FY Actual |
|---|---|---|
| Revenue | 750 | - |
| Operating Profit | - | - |
| Ordinary Income | - | - |
| Net Profit | - | - |
The company has provided a specific revenue target of JPY 750M for the next fiscal year. This target suggests an ambitious rebound, indicating strong confidence in the resumption of core business activities.
What to watch:
- Profitability Trajectory: The most critical focus for international investors must be the path to margin recovery. The substantial revenue rebound to JPY 750M must translate into a significantly improved Operating Margin to restore financial stability.
- Cash Flow Management: Given the decline in the Equity Ratio to 6.0%, monitoring the Cash Flow statement will be crucial to assess the company’s ability to fund operations and manage working capital through the period of revenue normalization.
- Demand Confirmation: Investors should view the management’s narrative regarding the sales delay—that demand remains intact—as the key takeaway. Future reporting must confirm that the market appetite for its regenerative medicine portfolio is robust enough to support the projected revenue growth.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.